Literature DB >> 6146391

Effects of midazolam on directly stimulated muscle biopsies from control and malignant hyperthermia positive patients.

J E Fletcher, H Rosenberg, M Hilf.   

Abstract

Midazolam is a water soluble benzodiazepine of interest to the anaesthetist for use as a premedicant and for induction of anaesthesia. The effects of midazolam were observed on the resting tension of directly stimulated muscle biopsied from control and malignant hyperthermia (MH) susceptible patients. In addition, interactions between midazolam and the two most commonly used MH diagnostic agents (halothane and caffeine) were examined. Midazolam, at maximum therapeutic concentrations (ca. 0.5 microgram X ml-1), had no detectable effects on muscle contraction in preparations from control or MH positive patients. Midazolam did elicit a contracture from control and MH positive preparations when used in a concentration range of 160-1280 micrograms X ml-1. There was no significant difference between control and MH positive patients in minimum concentration of midazolam causing contracture or the strength of contracture at the respective eliciting concentration. There appears to be no interaction between midazolam and either halothane or caffeine on the resting tension of the directly stimulated muscle twitch preparation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146391     DOI: 10.1007/bf03015405

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  9 in total

1.  Clinical, electroencephalographic, and pharmacokinetic studies of a water-soluble benzodiazepine, midazolam maleate.

Authors:  C R Brown; F H Sarnquist; C A Canup; T A Pedley
Journal:  Anesthesiology       Date:  1979-05       Impact factor: 7.892

2.  Editorial: Malignant hyperthermia: a pharmacogenetic disease of skeletal and cardiac muscle.

Authors:  B A Britt
Journal:  N Engl J Med       Date:  1974-05-16       Impact factor: 91.245

3.  Malignant hyperthermia: an investigation of five patients.

Authors:  B A Britt; W Kalow; A Gordon; J G Humphrey; N B Rewcastle
Journal:  Can Anaesth Soc J       Date:  1973-07

Review 4.  Skeletal muscle.

Authors:  A Sandow
Journal:  Annu Rev Physiol       Date:  1970       Impact factor: 19.318

Review 5.  Current concepts. The malignant hyperthermia syndrome.

Authors:  T E Nelson; E H Flewellen
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

6.  In vitro contracture tests for susceptibility to malignant hyperthermia.

Authors:  H Rosenberg; S Reed
Journal:  Anesth Analg       Date:  1983-04       Impact factor: 5.108

7.  Screening for malignant hyperthermia susceptibility.

Authors:  I L Anderson; R E Rawstron; D J Dunlop
Journal:  N Z Med J       Date:  1980-06-11

8.  Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle.

Authors:  B A Britt; L Endrenyi; W Frodis; E Scott; W Kalow
Journal:  Can Anaesth Soc J       Date:  1980-01

Review 9.  Malignant hyperthermia.

Authors:  G A Gronert
Journal:  Anesthesiology       Date:  1980-11       Impact factor: 7.892

  9 in total
  1 in total

1.  The benzodiazepine midazolam preferentially blocks inactivated Na channels in skeletal muscle fibre.

Authors:  A Duval; C O Malécot; L Perchenet; T Piek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.